Plain-English translation of NCT07156045 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing a new treatment called CAR-NK cell injection for men with metastatic castration-resistant prostate cancer — a type of advanced prostate cancer that continues to grow even after hormone therapy. The researchers want to see whether this medication is safe, how well patients tolerate it, and whether it can help slow or stop the cancer from growing.
Currently, there are no approved cell-based therapies specifically designed for this type of advanced prostate cancer in China. This trial exists to explore whether this new treatment approach might offer hope to patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive the CAR-NK cell treatment at the trial site. The trial involves a small group of 10 patients, and researchers will carefully monitor your safety and how your body responds to the medication. You will have regular clinic visits and tests to check your blood work, imaging, and overall health — though the exact schedule is not fully detailed in this summary.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China